Continuous combination oral contraceptive pills to eliminate withdrawal bleeding: A randomized trial

Obstetrics and Gynecology

Volumn 101, Issue 4, 2003, Pages 653-661

  Miller, Leslie ^a,b   Hughes, James P ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ETHINYLESTRADIOL PLUS LEVONORGESTREL; ORAL CONTRACEPTIVE AGENT;

ABDOMINAL PAIN; ACNE; ADULT; AMENORRHEA; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ENDOMETRIOSIS; FEMALE; HEADACHE; HISTOLOGY; HUMAN; LIBIDO DISORDER; MAJOR CLINICAL STUDY; MIGRAINE; MOOD DISORDER; MUSCLE CRAMP; ORAL CONTRACEPTION; PNEUMONIA; PRIORITY JOURNAL; PYELONEPHRITIS; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SPOTTING; TRANSVAGINAL ECHOGRAPHY; VOMITING; WEIGHT GAIN; WITHDRAWAL BLEEDING;

EID: 0037381248     PISSN: 00297844     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0029-7844(03)00014-0     Document Type: Article

References (33)

1. Combination oral contraceptive use and the risk of endometrial cancer. JAMA. 257:1987;796-800.
2. Kirstner R.W. The use of newer progestins in the treatment of endometriosis. Am J Obstet Gynecol. 75:1958;264-278.
3. Marks L.V. Sexual chemistry. A history of the contraceptive pill. 2001;Yale University Press, New Haven, Connecticut. 222.
4. Loudon N.B., Foxwell M., Potts D.M., Guild A.L., Short R.V. Acceptability of an oral contraceptive that reduces the frequency of menstruation The tri-cycle pill regimen. BMJ. 2:1977;487-490.
5. Coutinho E.M., Segal S.J. Is menstruation obsolete? 1999;Oxford University Press, New York. [original work published 1996].
6. Thomas S.L., Ellertson C. Nuisance or natural and healthy Should menstruation be optional for women? Lancet. 355:2000;922-924.
7. Kaunitz A.M. Menstruation Choosing whether.and when. Contraception. 62:2000;277-284.
8. Clarke A.K., Miller S.J. The debate regarding continuous use of oral contraceptives. Ann Pharmacother. 35:2001;1480-1484.
9. den Tonkelaar I., Oddens B.J. Preferred frequency and characteristics of menstrual bleeding in relation to reproductive status, oral contraceptive use, and hormone replacement therapy use. Contraception. 59:1999;357-362.
10. Sulak P.J., Scow R.D., Preece C., Riggs M.W., Kuehl T.J. Hormone withdrawal symptoms in oral contraceptive users, continuous use. Obstet Gynecol. 95:2000;261-266.
11. Miller L., Notter K. Menstrual reduction with extended use of combination oral contraceptive pills Randomized controlled trial. Obstet Gynecol. 98:2001;771-778.
12. Cachrimanidou A.C., Helberg D., Nilsson S., Waldenstrom U., Olsson S.E., Sikstrom B. Long interval treatment regimen with a desogestrel containing oral contraceptive. Contraception. 48:1993;205-215.
13. Staland B. Continuous treatment with natural oestrogens and progestogens. A method to avoid endometrial stimulation. Maturitas. 3:1981;145-156.
14. Sturdee D.W., Ulrich L.G., Barlow D.H., Wells M., Campbell M.J., Vessey M.P., et al. The endometrial response to sequential and continuous combined oestrogen progestogen replacement therapy. Br J Obstet Gynaecol. 107:2000;1392-1400.
15. Grace E., Emans S.J., Havens K.K., Merola J.L., Woods E.R. Contraceptive compliance with a triphasic and a monophasic norethindrone containing oral contraceptive pill in a private adolescent practice. Adolesc Pediatr Gynecol. 7:1994;29-33.
16. Rosenberg M.J., Meyers A., Roy V. Efficacy, cycle control, and side-effects of low and lower dose oral contraceptives A randomized trial of 20 mcg and 35 mcg estrogen preparations. Contraception. 60:2000;321-329.
17. Coutinho E.M., O'Dwyer E., Barbosa I.C., Gu Z.P., Shaaban M.M., Aboul-Oyoon M., et al. Comparative study on intermittent versus continuous use of a contraceptive pill administered by vaginal route. Contraception. 51:1995;355-358.
18. Vercellini P., De Giorgi O., Mosconi P., Stellato G., Vicentini S., Crosignani P.G. Cyproterone acetate versus a continuous monophasic oral contraceptive in the treatment of recurrent pelvic pain after conservative surgery for symptomatic endometriosis. Fertil Steril. 77:2002;52-61.
19. Lang J.M., Buring J.E., Rosner B., Cook N., Hennekens C.H. Estimating the effect of the run-in on the power of the physicians' health study. Stat Med. 10:1991;1585-1593.
20. Belsey E.M., Machin D., d'Arcangues C. The analysis of vaginal bleeding patterns induced by fertility regulating methods. Contraception. 34:1986;253-261.
21. Reisman H., Martin D., Gast M.J. A multicenter randomized comparison of cycle control and laboratory findings with oral contraceptive agents containing 100 mcg levonorgestrel with 20 mcg EE2 or triphasic norethindrone with EE2. Am J Obstet Gynecol. 181:1999;S45-S52.
22. Potter L., Oakley D., de Leo-Wong E., Canamar R. Measuring compliance among oral contraceptive users. Fam Plann Perspect. 28:1996;154-158.
23. Trussell J, Kowal D. The essentials of contraception. In: Hatcher RA, Trussell J, Stewart F, Cates W Jr, Stewart GK, Guest F, et al, eds. Contraceptive technology. 17th rev ed. New York: Ardent Media Inc., 1998:216.
24. Coney P., DelConte A. The effects on ovarian activity of a monophasic oral contraceptive with 100 mcg levonorgestrel and 20 mcg EE2. Am J Obstet Gynecol. 181:1999;S53-S58.
25. Schwartz J.L., Creinin M.D., Pymar H.C., Reid L. Predicting risk of ovulation in new start oral contraceptive users. Obstet Gynecol. 99:2002;177-182.
26. Fruzzetti F., Genazzani A.R., Ricci C., De Negri F., Bersi C., Carmassi F. A 12 month clinical investigation with a 24 day regimen containing 15 mcg EE2 plus 60 mcg gestodene with respect to hemostasis and cycle control. Contraception. 63:2001;303-307.
27. Killick SR, Bancroft K, Oelbaum S, Morris, Elstein M. Extending the duration of the pill-free interval during combined oral contraception. Adv Contracept 1990;6:33-40.
28. Bracken M.B. Oral contraception and congenital malformations in offspring A review and meta-analysis of the prospective studies. Obstet Gynecol. 76:1990;552-557.
29. Raman-Wilms L., Tseng A.L., Wighardt S., Einarson T.R., Koren G. Fetal genital effects of first trimester sex hormone exposure A meta-analysis. Obstet Gynecol. 85:1995;141-149.
30. Moyer D.L., De Legnieres B., Driquez P., Pez J.P. Prevention of endometrial hyperplasia by progesterone during long term estradiol replacement Influence of bleeding pattern and secretory changes. Fertil Steril. 59:1993;992-997.
31. Doren M., Reuther G., Minne H.W., Schneider H.P.G. Superior compliance and efficacy of continuous combined oral estrogen progestogen replacement therapy in postmenopausal women. Am J Obstet Gynecol. 173:1995;1446-1451.
32. Beral V., Hermon C., Kay C., Hannaford P., Darby S., Reeves G. Mortality associated with oral contraceptive use 25 year follow up of cohort of 46,000 women from Royal College of General Practitioner's oral contraceptive study. BMJ. 318:1999;96-100.
33. Cachrimanidou A.C., Hellberg D., Nilsson S., von Schoulz B., Crona N., Siegbahn A. Hemostasis profile and lipid metabolism with long-interval use of a desogestrel-containing oral contraceptive. Contraception. 50:1994;153-165.